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Virus, protein foldingViruses are intracellular pathogens responsible for a vast number of human diseases. Due to their small ge-
nome size, viruses rely primarily on the biosynthetic apparatus of the host for their replication. Recent
work has shown that the molecular chaperone Hsp90 is nearly universally required for viral protein homeo-
stasis. As observed for many endogenous cellular proteins, numerous different viral proteins have been
shown to require Hsp90 for their folding, assembly, and maturation. Importantly, the unique characteristics
of viral replication cause viruses to be hypersensitive to Hsp90 inhibition, thus providing a novel therapeutic
avenue for the development of broad-spectrum antiviral drugs. The major developments in this emerging
ﬁeld are hereby discussed. This article is part of a Special Issue entitled: Heat Shock Protein 90 (HSP90).
© 2011 Elsevier B.V. All rights reserved.1. Introduction
The capacity of all proteins to carry out their function is dependent
on their ability to fold correctly and folding of many cellular proteins
critically relies on the assistance of molecular chaperones. Molecular
chaperones are highly conserved and often essential for viability
and for the ability to survive cellular stress. Chaperones reside in all
cellular compartments where they promote the folding, maturation,
complex assembly, and trafﬁcking of proteins in an ATP dependent
manner [1–3]. In addition, chaperones provide a conduit to the pro-
tein degradation machinery and regulate many cellular pathways [3].
Viruses are intracellular obligate parasites that hijack the biosynthetic
machinery of the host for their replication. Given the structural and func-
tional complexity ofmany viral proteins, it is not surprising that they, like
cellular proteins, are also dependent on chaperones for their folding and
function. In this review we discuss the role of Hsp90 in viral replication
and the potential of targeting Hsp90 as an antiviral strategy.
2. Hsp90: overview of cellular functions
Hsp90s are a family of highly abundant, essential, and evolution-
arily conserved molecular chaperones. In mammals, there are twohock Protein 90 (HSP90).
and BioX Program, Stanford
d, CA 94305, United States.
).
l rights reserved.cytoplasmic Hsp90 isoforms, the stress inducedHsp90α and the consti-
tutively expressed Hsp90β [4], as well as an ER resident homologue
Grp94 (also called gp96) [5], and a mitochondrial variant, TRAP1 [6].
Hsp90s are ATPases that mostly form homodimeric complexes, with
each monomer sharing a common domain organization comprised of
a C terminal dimerization domain, a middle domain, and a structurally
unique N terminal ATPase domain (see review [7,8]). In the cytoplasm,
Hsp90 regulates the activity, maturation, localization, and turnover of a
large yet select set of substrates or “clients” [9,10]. Hsp90 function is
regulated by a cohort of co-chaperones that modulate its ATPase cycle,
enable client acquisition and selection, and provide a link to other chap-
erone systems as well as the ubiquitin–proteasome system [11–13].
Hsp90 is believed to recognize ametastable structural element in its cli-
ents rather than a primary amino acid sequence. Unlike other chaper-
one systems in the cell, Hsp90 does not appear to interact with newly
synthesized proteins. Instead, Hsp90 receives its client proteins
from other chaperone systems, such as Cdc37 or the co-
translationally acting Hsp70 chaperone system, likely following the
acquisition of a partially folded state recognized by Hsp90. Thus,
some of the client speciﬁcity of Hsp90 is determined by these collab-
orating chaperones. For protein kinases, which comprise the most
intensely studied client group, binding to Hsp90 requires the Cdc37
co-chaperone, which binds to both Hsp90 and protein kinase clients
[14]. For other clients, such as steroid hormone receptors, Hsp70
binds ﬁrst, and the co-chaperone Hop bridges transfer to Hsp90.
Hop physically interacts with both chaperone systems by virtue of
speciﬁc tetratricopeptide (TPR) interaction domains that recognize
the C-terminal tails of both Hsp70 and Hsp90 [15,16]. In addition to
its role in assisting the maturation of proteins, Hsp90 was shown to
be speciﬁcally required for the degradation of certain proteins [17].
699R. Geller et al. / Biochimica et Biophysica Acta 1823 (2012) 698–706In this regard, it is noteworthy that CHIP, another TPR containing
protein that binds to Hsp90 also contains a U-box domain with E3
ubiquitin ligase activity. CHIP has been shown to direct Hsp90 and
Hsp70 bound proteins to proteasomal degradation [18].
The cellular functions and targets of Hsp90 are highly diverse. In
addition to its originally described function assisting the maturation
of protein kinases and steroid hormone receptors [19], Hsp90 is re-
quired for the function of a large number of proteins and protein com-
plexes, both under normal growth conditions and under conditions of
stress, such as elevated temperatures. Hsp90 clients include proteins
involved in transcription, translation, mitochondrial function, kineto-
chore assembly, centrosome function and cell cycle [20–22]. Hsp90 is
also central to secretory pathway function and associates with many
complexes involved in membrane trafﬁcking [3,22]. Many of the
Hsp90 clients are part of multisubunit complexes. The current under-
standing of Hsp90 function as a chaperone that stabilizes or remodels
polypeptides that are substantially folded suggests that its action pro-
motes a conformational maturation step that enables clients to bind
ligands, interact with cofactors, or carry out their biological function
[23]. For instance, many clients of Hsp90 undergo ordered assembly
and disassembly processes, and Hsp90 may stabilize subunits of
these complexes prior to assembly or facilitate their conformational
transitions [24]. During cellular stress, e.g. at elevated temperatures,
Hsp90 may also become important to stabilize the labile conforma-
tions of many proteins, most notably cell cycle components. In this re-
gard, it is noteworthy that aberrant proteins with a few amino acid
changes exhibit radically higher dependence on Hsp90 than their na-
tive counterparts [25].
Among the Hsp90 clientele identiﬁed to date are many proteins in-
volved in signal transduction and cell division, including numerous pro-
teins related to tumorigenesis [26,27]. The dependence of multiple
oncogenes on Hsp90 renders cancer cells hypersensitive to Hsp90 inhi-
bition and forms the basis for using Hsp90 inhibitors in cancer treat-
ment. Numerous speciﬁc pharmacological inhibitors of Hsp90 have
been identiﬁed. The majority of these, including radicicol, Geldanamy-
cin (GA), and the GA derivatives 17-allyl-17-demethoxygeldanamycin
`(17-AAG) and 17-desmethoxy-17-N,N-dimethylaminoethylamino-
geldanamycin (17-DMAG), inhibit Hsp90 activity by competing with
ATP for binding to the N-terminal ATP/ADP-binding domain of
Hsp90 (see [28] for review). Inhibitors that bind to the C-terminal
domain, such as novobiocin and coumermycin A1, have also been
identiﬁed. Due to the fact that many Hsp90 clients are involved in
cancer progression, these inhibitors possess broad anticancer activ-
ity and several are currently undergoing advanced stage clinical
evaluation [26,29].
3. Hsp90 in viral replication
Viral proteins, like cellular proteins, are dependent on chaperone
function for folding and assembly [30]. Hsp90 has been shown to
play a role in the replication of many different viruses including
DNA viruses, RNA viruses of both positive and negative sense ge-
nomes, and double-stranded RNA viruses (see Table 1). In fact, the
dependence of viruses on Hsp90 appears to be nearly universal. Strik-
ingly, for viruses tested to date, replication appears to be sensitive to
Hsp90 inhibitors at concentrations not affecting cellular viability. The
hypersensitivity of viral replication to Hsp90 inhibition may stem
from several unique characteristics of viral protein homeostasis,
which present a distinct set of challenges to the protein folding ma-
chinery, and thus render it more sensitive to ﬂuctuations in cellular
folding capacity. First, the limited size of most viral genomes often de-
termines that viral proteins be multifunctional, likely resulting in
structurally complex proteins that are dependent on chaperone func-
tion. In addition, many viruses, and in particular cytopathic viruses,
must produce large quantities of a limited number of viral proteins
within a short period of time. The need to rapidly produce a limitedarray of structurally complex proteins in high abundance is likely to
tax the capacity of the chaperone systems required to fold them.
Moreover, the unique complexity and structural requirements of
viral capsids make their precursors particularly vulnerable to aggre-
gation and misfolding [31–34]. Thus, capsid proteins must fold to a
precursor conformation that is soluble yet poised to assemble in the
presence of the viral genome to form a capsid, which may contain
over 1000 identical subunits and retain infectivity despite extreme
thermal and chemical conditions [35]. The high mutation rates of
RNA viruses, which are the highest in nature, inevitably lead to the
production of a swarm of mutant viral proteins during infection.
Such viral population diversity has been shown to be critical for the
ability of viruses to adapt to adverse conditions [36–38]. However,
the mutant proteins thus generated can have dominant negative ef-
fects on viral protein complex assemblies [39]. As mutant proteins
are known to be hyperdependent on chaperone function for activity
[25], chaperones are likely to be instrumental in buffering the delete-
rious effects of mutant viral proteins and thus facilitate viral adapta-
tion. Finally, since chaperones regulate many cellular functions
including signaling networks, cell cycle progression, and apoptosis,
viruses are likely to manipulate chaperones to render cells conducive
to viral replication.
While the antiviral effects of Hsp90 inhibition have been broadly
demonstrated, detailed understanding of the role of Hsp90 in viral
replication is only available for a few viruses. In most cases, the anti-
viral activity of Hsp90 inhibitors is accompanied by the degradation
of a single viral protein, implicating such viral proteins as dependent
on Hsp90 for their maturation or stability. The major categories of
viral Hsp90 clients are outlined below.
4. Viral non-structural proteins as Hsp90 clients
4.1. Viral polymerases
Viral polymerases constitute the largest class of identiﬁed Hsp90
viral client proteins. The role of Hsp90 in the function of viral poly-
merases appears to be variable, although detailed knowledge is only
available in a few cases. The best-elucidated example of Hsp90's
role in polymerase function comes from the reverse transcriptases
(RT) of two viruses belonging to the Hepadnaviridae family: duck
hepatitis B virus (DHBV) and human hepatitis B virus (HBV). These
enzymes mediate both the incorporation of viral pregenomic RNA
(pgRNA) into nucleocapsids and the reverse transcription of pgRNA
into DNA [40]. For DHBV, Hsp90 stimulates the ability of the RT to ini-
tiate and maintain stable reverse transcription. This function of Hsp90
requires the presence of other chaperones, such as Hsp70 and Hsp40,
and co-chaperones Hop and p23, which together function as sub-
strate release factors and facilitated incorporation of the pgRNA into
nucleocapsids [41–43]. The Hsp90 cofactor Cdc37, normally required
for the folding of Hsp90 dependent cellular kinases, was also shown
to interact with the DHBV RT independently of Hsp90 [44]. Overex-
pression of Cdc37 resulted in increased reverse transcription and
pgRNA packaging into nucleocapsids, while overexpression of a dom-
inant negative Cdc37 mutant had opposite effects. For HBV, Hsp90 in-
hibition with GA has been shown to reduce both reverse transcription
and pgRNA incorporation into nucleocapsids. Furthermore, the pro-
duction of active reverse transcriptase in vitro requires the addition
of recombinant Hsp90, Hsp70, Hsp40, Hop and p23, similar to DHBV
[45,46].
The polymerase of inﬂuenza virus A also requires Hsp90 for ge-
nome replication (Fig. 1A). The RNA dependent RNA polymerase of
inﬂuenza virus is comprised of three subunits, PB1, PB2 and PA.
Hsp90 associates with both PB1 and PB2 in infected cells and re-
localizes to the nucleus where it facilitates viral RNA synthesis
[47,48]. Hsp90 inhibition by treatment with GA or 17-AAG was
shown to enhance the degradation of both PB1 and PB2 as well as
Table 1
Summary of the viruses and viral proteins currently known to require the Hsp90 chaperone.
Viral family Virus Viral protein Hsp90 dependent process Additional factor References
Herpesviridae HSV1/HSV2 UL30 Polymerase localization Hsp70, BAG3 [51,52,57]
VZV ORF29F Localization of orf29 Hsp70, BAG3 [54]
HCMV – Expression of immediate early protein IE2 PI3K [53]
EBV KH Apoptosis prevention – [96,111]
EBNA Cell proliferation – [112]
KSHV KI Apoptosis prevention Hsp40 [94]
v-FLIP Apoptosis prevention IKK, Cdc37 [93]
Polyomaviridae SV40 LT Stabilization of LT protein – [63]
Poxviridae Vaccinia virus 4a core protein Capsid assembly/virus gene expression Hsp70 [34,113]
Reoviridae Reovirus σ1 C′ trimerization of σ1 Hsp70, p23 [76–79]
Rotavirus NSP3 Dimerization of NSP3 – [66]
– – PI3K [70]
Birnaviridae IBDV VP2 (capsid) Virus internalization – [88]
Picornaviridae Poliovirus P1 capsid protein Cleavage of P1 into VP1, VP2 and VP3 p23 [33]
Rhinovirus P1 capsid protein Cleavage of P1 into VP1, VP2 and VP3 p23 [33]
Coxsackievirus P1 capsid protein Cleavage of P1 into VP1, VP2 and VP3 p23 [33]
Flaviviridae HCV NS3 protease Cleavage at NS2/3 junction, NS3 function – [71,72,99]
NS5A Replication complex formation/genome replication FKBP8/hB-ind1 [73,74,114,115]
DENV Viral receptor Virus internalization Hsp70/GRP78 [85,86]
Arenaviridae LCMV NP Antigen cross presentation – [116]
Nodaviridae FHV Protein A Replication complex formation – [58,59,117]
Hepeviridae HEV Capsid Intracellular transfer – [82]
Rhabdoviridae VSV L protein Protein stabilization – [60]
Paramyxoviridae HPIV2/3 L protein Protein stabilization – [60]
SV5/41 L protein Protein stabilization – [60]
Measles virus – Enhanced oncolytic activity – [118]
Sendai virus – Innate immunity activation TBK1 [110]
Bunyaviridae La Crosse virus L protein Protein stabilization – [60]
Orthomyxoviridae Inﬂuenza A virus PB1, PB2 Nuclear localization – [47]
vRNP complex formation – [48]
RNA synthesis – [49]
Filoviridae Ebola virus – Virus propagation – [119]
Retrovirus HTLV1 Tat Transcription – [95]
HIV1 Tat Transcription/Cell survival – [89,90,120]
Hepadnaviridae DHBV P protein Reverse transcriptase priming p23, Cdc37, Hsp40, Hsc70 [41,43,44,121]
HBV P protein Reverse transcriptase priming Hsp70, Hsp40
Hop, P23
[43,45,46]
Abbreviations: HSV, herpes simplex virus; VZV, varicella zoster virus; HCMV, human cytomegalovirus; EBV, Epstein-Barr virus; KSHV, Kaposi sarcoma-associated herpesvirus; SV,
simian virus; IBDV, infectious bursal disease virus; HCV, hepatitis C virus; DENV, dengue virus; LCMV, lymphocytic choriomeningitis virus; FHV, ﬂock house virus; HEV, Hepatitis E
virus; VSV, vesicular stomatitis virus; HPIV, human parainﬂuenza virus; vRNP, viral ribonucleoprotein complex; HTLV, human adult T cell leukemia virus; HIV, human immunode-
ﬁciency virus; DHBV, duck hepatitis B virus; HBV, hepatitis B virus.
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ducing the levels of viral derived RNAs [49].
Hsp90 is important for the polymerase functions of Herpesviridae
family. The alpha herpesvirus, herpes simplex virus type 1 (HSV-1)
induces formation of speciﬁc chaperone-rich nuclear structures called
“Virus-induce Chaperone enriched” (VICE) compartments, which ap-
pear to facilitate viral replication in the nucleus and nuclear protein
quality control [50]. During HSV infection, a subpopulation of Hsp90
localizes to VICE compartments and its ATPase activity is required
for the proper nuclear localization of viral DNA-dependent DNA poly-
merase, UL30. Inhibition of Hsp90 with GA results in mislocalization
of the viral polymerase to the cytoplasm instead of the nucleus, pro-
teasomal degradation of the polymerase, and consequent reduction
of viral DNA replication and production of progeny viral particles
[51,52]. Hsp90 is also required for replication of beta-herpesviruses.
Hsp90 inhibition with GA led to degradation of the viral polymerase
as well as reduced viral gene expression via the disruption of PI3-
kinase pathway during human cytomegalovirus (HCMV) infection
[53]. Whether Hsp90 is required for the nuclear localization of the
HCMV polymerase, as in the case of HSV1, remains to be tested. On
the other hand, during the infection with another alpha-herpesvirus,
varicella zoster virus (VZV), the viral single-stranded DNA binding
protein ORF29p was shown to colocalize with Hsp90 and Hsp70 in
the nucleus through a speciﬁc interaction with BAG3 [54]. BAG3 is one
of a cohort of Hsp70 interacting Bag-family proteins that modulateHsp70 function [55,56]. Hsp90 inhibition by treatment with GA or
17-DMAG resulted in diffuse cytosolic localization of ORF29p and
BAG3, suggesting that herpesvirus DNA binding proteins may generally
require Hsp90 for nuclear import. BAG3 co-immunoprecipitates with
ICP0, the HSV E3 ubiquitin ligase and major pathogenicity factor, but
whereas knockdown of BAG3 reduced the replication of VZV it did
not affect wild type HSV replication [57]. This raises the possibility
that viruses utilize different chaperone complexes for the same pur-
pose. It will be of interest to establish whether the polymerases of
herpesviruses require Hsp90 for folding and/or nuclear localization
directly, or whether Hsp90 is required for the folding or activity of
cellular factors required for polymerase stability or nuclear import.
Protein A, the RNA dependent RNA polymerase protein of the
Nodaviridae ﬂock house virus (FHV), is also dependent on Hsp90. In-
terestingly, in the case of FHV, Hsp90 appears to be required for trans-
lation of protein A but not for substantial polymerase activity [58].
Inhibition of Hsp90 with GA during FHV infection results in reduced
levels of polysomes translating protein A, while no effect is observed
on other viral proteins or cellular RNA associated with polysomes
[59]. Whether the role of Hsp90 in protein A synthesis is due to a di-
rect effect on protein A or via the chaperoning of a cellular factor is
unknown. In addition to the above examples, other viral families
also require Hsp90 for polymerase activity, since pharmacological in-
hibition of Hsp90 by GA during infection results in the degradation of
the RNA-dependent RNA polymerases of rhabdoviruses (vesicular
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Fig. 1. Distinct functions of Hsp90 during viral replication. (A) Hsp90-facilitates assembly of inﬂuenza polymerase. Newly made inﬂuenza PB2 interacts with Hsp90 in the cytoplasm
and the complex translocates into the nucleus. Another polymerase subunit PB1, which itself interacts with Hsp90, is also transported into the nucleus together with the PB2/Hsp90
complex. Once in the nucleus, Hsp90 dissociates as PB2 binds to PB1/PA to form the trimeric active polymerase. Inset: the two conformations of Hsp90 are regulated by its ATPase
cycle. (B) Formation of a multi-chaperone complex with non-structural protein NS5A during HCV replication. HCV NS5A assembles into a complex containing Hsp90, FKBP8 and hB-
ind1. Interaction with FKBP8 is required for NS5A entry into the Hsp90 cycle whereas hB-ind1 action stimulates dissociation from Hsp90 and correct NS5A folding (NS5A*), leading
incorporation into an active replication complex (RC) containing other NS proteins and host factors (HFs). (C) Role of Hsp90 in picornavirus capsid maturation. Picornavirus capsid
precursor poly-protein P1 binds associates with Hsp90, likely following an upstream interaction with Hsp70. Hsp90 is required to fold P1 to a mature conformation (P1*) that is
competent for proteolytic cleavage by the viral protease (3CPro) into the mature capsid protein. The processed capsid proteins no longer interact with Hsp90.
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simian virus 5 and 41), and bunyaviruses (La Crosse virus), and the
concomitant suppression of viral propagation [60].
The dependence of viral polymerases on Hsp90 is very striking as
it extends to the RNA-dependent RNA polymerases of both positive
and negative-strand RNA viruses, DNA-dependent DNA polymerases,
as well as to the reverse transcriptase of hepadnaviruses, despite the
evolutionary, structural and functional divergence of these proteins.
In this regard, viral polymerases may share features of their cellularcounterparts, as telomerase and DNA polymerase α are known
Hsp90 client proteins [61,62]. The general dependence of many poly-
merases on Hsp90 suggests that this chaperone may recognize a con-
served feature of these diverse enzymes, or may facilitate a common
step in their maturation and/or mechanism, such as the interaction
with nucleic acid. However, not all viral polymerases require Hsp90
for their function [33]. Nonetheless, it will be of interest to elucidate
the reason underlying the wide dependence of polymerases function
on hsp90.
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Hsp90 is also required for the activity and folding of non-
structural proteins other than polymerases. In the case of the DNA
tumor virus SV40, Hsp90 associates with the large T antigen (LT)
[63]. LT protein is a multifunctional protein that interacts with several
cellular proteins, including the chaperones Hsp70 and Hsp90, as well
as regulatory proteins, such as p53 and DNA polymerase α [64,65].
Hsp90 physically interacts with LT and Hsp90 inhibition with GA or
radicicol leads to its degradation in cells. Similarly, for rotavirus, non-
structural protein 3 (NSP3) also requires Hsp90 for folding and stabi-
lization [66]. NSP3 shuts off cellular translation by relocalizing the
cytoplasmic poly(A) binding protein (PABP-C1) to the nucleus, there-
by evicting it from translation initiation complexes in infected cells
[67–69]. Inhibition of Hsp90 by 17-AAG or 17-DMAG resulted in re-
duced NSP3 translation and abolishes nuclear translocation of PABP-
C1, thus suppressing viral replication [66,70].
In the case of hepatitis C virus (HCV), Hsp90 is required for the ac-
tivity and stability of two non-structural proteins, the protease and
helicase NS3 and the multifunctional protein NS5A (Fig. 1B). Inhibi-
tion of Hsp90 by GA, 17-AAG, or radicicol reduced the protease activ-
ity of NS3 required to liberate it from the NS2/3 protein precursor,
and caused NS3 proteasomal degradation [71,72]. Interestingly,
even though Hsp90 is required for the proteolytic activity of NS3,
Hsp90 binds the helicase domain and not the protease domain. Ac-
cordingly, deletion of the helicase domain prevents the degradation
of NS3 induced by Hsp90 inhibitors. NS5A also associates with
Hsp90 and Hsp90 inhibition by GA results in a modest level of NS5A
degradation [73]. As discussed above for the polymerase–Hsp90 in-
teractions, the study of HCV encoded clients of Hsp90 also implicates
speciﬁc Hsp90 co-chaperones in viral replications. Interestingly, the
analysis of the NS5A–Hsp90 interactions revealed a novel type of
membrane-anchored Hsp90 complex, where Hsp90 and NS5A are
both associated with the proline-isomerase FKBP8 and a novel
membrane-bound Hsp90 cofactor called human butyrate-induced
transcript 1 (hB-ind1), which harbors a p23 homology domain [74].
These ﬁndings illustrate how the large collection of Hsp90 cofactors
can direct individual viral proteins to speciﬁc cellular locales and
functions. It is also noteworthy that replication of all positive-strand
RNA viruses, such as HCV, occurs on intracellular membranes, raising
the possibility that membrane-anchored Hsp90 cofactors, such as hB-
ind1, target the chaperone to sites of viral replication and help assem-
ble large replication complexes. Investigating the role of hB-ind1 and
other Hsp90 cofactors in the replication of additional RNA viruses
may lead to more speciﬁc therapeutic avenues to inhibit viral replica-
tion, since inhibition of speciﬁc Hsp90–cochaperone interactions
could reduce pleiotropic adverse effects on the protein homeostasis
of uninfected cells.
5. Viral structural proteins as Hsp90 clients
Viral structural proteins assemble to form the viral capsid, a com-
plex protein structure that encapsulates the viral genome, protecting
it from degradation and releasing it upon re-infection of a new cell.
Viral capsids can be comprised of one or more proteins and can con-
tain over 1000 subunits. These structures must be sufﬁciently stable
both within the host and outside to withstand harsh environmental
conditions, such as low pH and high temperature, and yet they
must also disassemble readily upon entry into cells to deliver the
viral genome. Therefore, the complexity of viral capsids is likely to
be especially demanding on the cellular protein folding and assembly
machinery.
Hsp90 is known to facilitate folding of several viral structural
proteins. Hsp90 is required for replication of Picornaviridae family
members poliovirus, rhinovirus, and coxsackievirus [33]. Mechanistic
analyses of poliovirus and rhinovirus replication traced the Hsp90requirement to a role in the maturation of the viral capsid proteins
[33] (Fig. 1C). The picornavirus capsid consists of 60 copies of each
of four subunits, which are generated by the cleavage of the P1 pre-
cursor protein by a viral encoded protease. Hsp90, in combination
with the p23 co-chaperone, was found to interact with P1 and to be
required for the cleavage of P1 into the capsid subunits by the viral
protease. Interestingly, Hsp90 did not interact with any other viral
proteins and its inhibition did not affect the cleavage of virus encoded
precursor proteins that are similarly cleaved by the same viral protease.
Hence, as protease activity is not diminished with other viral pro-
teins, it is likely that Hsp90 is required for inducing a P1 conﬁrma-
tion that enables recognition and/or cleavage by the protease [33].
Moreover, following cleavage, Hsp90 is no longer associated with
the mature, cleaved capsid subunits, suggesting that Hsp90 recog-
nizes a state of P1 that is lost following cleavage. Since the Picorna-
viridae family is the largest viral family and both capsid structure
and maturation pathway are conserved within this family, the wealth
of sequence and structural information make P1 an interesting model
for studying Hsp90–substrate interactions. It is interesting to note,
however, that hepatitis A replication is not sensitive to Hsp90 inhi-
bition; this hepatovirus is distinguished from other Picornaviridae in
its extremely inefﬁcient translation and replication kinetics, and may
accordingly employ alternative strategies for P1 maturation [75].
The reovirus attachment protein σ1 also requires Hsp90 for fold-
ing. The σ1 protein forms a homotrimeric complex that decorates
the viral capsid and mediates binding to host cell receptors [31,32].
The folding of the σ1 protein occurs in a stepwise manner: upon syn-
thesis on polysomes the emerging nascent chains begin to trimerize
co-translationally, forming a folded, trimeric N-terminal domain;
subsequently to completion of translation the C-terminal domain
folds and trimerizes post-translationally [76,77]. Notably, Hsp90 is es-
sential for the post-translational folding step of the C-termini [78].
Accordingly, inhibition of Hsp90 blocks folding of the C-termini but
does not affect trimerization of the N-terminal domain. Hsp90 recog-
nizes a conformation that is lost upon folding and does interact with
fully assembled σ1 trimers. Strikingly, translation of σ1 leads to
Hsp90 phosphorylation, which in turn blocks the Hsp90-σ1 interac-
tion, suggesting a possible novel feedback mechanism to release
Hsp90 upon σ1 folding [79].
During vaccinia virus infection, inhibition of Hsp90 by GA or novo-
biocin reduces viral DNA replication by speciﬁcally inhibiting inter-
mediate and late gene expression but not early gene expression
[80,81]. Hsp90 interacts with the 4a core protein of vaccinia virus, im-
plicating Hsp90 in the conformational maturation of the vaccinia cap-
sid. Furthermore, Hsp90 only colocalizes with the viral core protein
4a early during infection but not at later stages, suggesting a transient
role for Hsp90 in virion morphogenesis [34]. Since vaccinia virus en-
codes over 250 proteins, it remains likely that Hsp90 and other chap-
erones play additional roles in the replication of this virus.
While all the above ﬁndings illustrate a role of Hsp90 in viral cap-
sid folding and assembly, it is also possible that Hsp90 associates with
viral capsids at an early entry step such as penetration or uncoating,
in which capsids must be transported in the cell and disassembled.
This has in fact been suggested for hepatitis E virus (HEV), where
Hsp90 appears important for intracellular transport of the incoming
viral particle [82].
6. Cellular factors associated with viral propagation, pathogenesis
and the immune system
In addition to a direct interaction with viral proteins that mediates
their folding, assembly and activity, Hsp90 can also facilitate or mod-
ulate infection through regulation of host processes and cellular
Hsp90 client proteins. The examples below illustrate the plurality of
levels at which Hsp90 regulates viral infection. First, Hsp90 was
reported to be present on the surface of some cells [83]. While the
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surface is not fully clear, plasma membrane associated Hsp90 and
Hsp70 have been observed in both stressed and antigen-presenting
cells [84]. Such surface exposed Hsp90 is proposed to play a role
in the internalization of both dengue virus (DENV) and infectious
bursal disease virus (IBDV) [85,86]. In the case of dengue virus,
the cell-surface Hsp90 is proposed to interact with an unknown
viral receptor complex [86]. Addition of anti-Hsp90α or Hsp70 anti-
bodies to the extracellular medium inhibits virus infection in mono-
cytes and macrophages but does not affect dengue virus propagation
in liver cells, suggesting a cell type speciﬁc requirement for plasma
membrane localized Hsp90 [85]. Moreover, transient heat shock was
shown to increase cell surface expression of Hsp90 and Hsp70 and
also increase dengue virus infectivity [87]. Similar to dengue virus, anti-
bodies against Hsp90α were shown to inhibit the ability of IBDV to
infect a cell line of chicken origin [88].
Hsp90 was implicated in supporting the efﬁcient production of
human immunodeﬁciency virus (HIV) proviral DNA by promoting
the formation of a Cdk9/cyclin T1 complex, the components of the
human positive transcription elongation factor P-TEFβ [89]. This com-
plex phosphorylates cellular RNA polymerase II, resulting in its in-
creased processivity. The HIV accessory protein Tat can then recruit
P-TEFβ to the 5′ of HIV RNA and stimulate transcription of HIV provi-
ral DNA. Hsp90, together with the co-chaperone Cdc37, was shown to
bind Cdk9 and render it competent for binding cyclin T1. Inhibition of
Hsp90 impaired formation of Cdk9/cyclin T1 complexes. While the
relevance of this ﬁnding to HIV replication is unknown, Hsp90 inhibi-
tion by GA and coumermycin A1 was reported to reduce the replica-
tion of HIV [89,90].
Viruses causing chronic infection might take advantage of chaper-
one machinery to modulate host cell viability to ensure persistence of
the viral infection. Since Hsp90 modulates the activity of many signal
transduction pathways and immune modulators, Hsp90 inhibitors
may help clear such chronic viral infections. For instance, both the
glycoprotein K1 and the viral FLIP protein (v-FLIP) of the gamma her-
pesvirus Kaposi sarcoma-associated herpesvirus (KSHV) activate the
NF-kB pathway and block apoptosis to ensure survival of infected
host cells [91,92]. v-FLIP forms an IKK kinase complex with assistance
of Hsp90 and Cdc37 [93]. Hsp90, together with other chaperones such
as Hsp40, also interacts with K1 and prevents its proteasomal degra-
dation [94]. Accordingly, inhibitors of Hsp90 block the activity of K1
and v-FLIP. As a result, NF-kB activation is impaired and apoptosis
of infected cells is increased, helping clear the viral infection. Similar
to KSHV, Epstein Barr virus (EBV) and human T-cell leukemia virus
(HTLV)-1 also exploit Hsp90 function to promote survival of infected
host cells thus prolonging the viral infection [95,96].
7. Potential of Hsp90 inhibitors as antivirals
Viral infections are among the principal causes of human morbid-
ity and mortality worldwide and impose severe economic burdens on
society. Despite their importance, few effective antivirals currently
exist and many medically and economically important viral infections
lack any treatment (see [97] for review). One of the main hurdles to
the development of effective antivirals is the rapid acquisition of
drug resistance by viruses, which can limit the utility of even the
most effective drugs and preclude their long-term use [98]. The
high mutation rates, short replication times, large population sizes,
and compact genomes enable viruses to rapidly acquire mutations
conferring drug resistance, thus circumventing inhibition by antiviral
drugs. The ability of viruses to develop drug resistance to antiviral
compounds targeting viral proteins is enormous, since the drug target
is under the replicative control of the virus and therefore escape mu-
tations are easily generated. In the case of antivirals targeting cellular
factors required for viral replication, acquisition of drug resistance has
also been observed, although it is more difﬁcult as the virus musteither dispense with the affected function or evolve to employ an al-
ternative cellular pathway. The lack of successful antiviral therapies
for most viruses create a pressing need for identiﬁcation of novel an-
tivirals that do not elicit drug resistance.
Inhibition of Hsp90 constitutes a promising antiviral approach.
First, as can be inferred from the multiplicity of different viruses re-
quiring Hsp90 for replication, Hsp90 inhibitors are among the
broadest-spectrum antivirals identiﬁed to date. Currently, Hsp90 in-
hibitors have been demonstrated to possess antiviral activity in tissue
culture against picornaviruses (poliovirus, coxsackievirus, rhinovi-
rus), inﬂuenza virus, paramyxoviruses (HPIV2, HPIV3, SV5, SV41),
HCV, Ebola virus, vesicular stomatitis virus, La Crosse virus, severe ac-
quired respiratory syndrome (SARS), FHV, HIV, vaccinia virus, and
herpes viruses (HSV1/2, HCMV, VZV). This property makes Hsp90 in-
hibitors particularly attractive antivirals for existing viral diseases
lacking therapies and for rapid response to newly emerging viral dis-
eases. Secondly, administration of Hsp90 inhibitors to infected ani-
mals was shown to reduce the replication of two different viruses,
poliovirus and HCV, with little toxicity to the infected host [33,99].
These experiments highlight the feasibility of using these inhibitors
therapeutically in humans. Thirdly, Hsp90 inhibitors were demon-
strated to be refractory to the development of drug resistance. This
was clearly highlighted by poliovirus experiments, as this virus has
been demonstrated to gain drug resistance to all antivirals tested to
date whether they target viral or host factors. However, when polio-
virus was repeatedly treated with Hsp90 inhibitors, no drug resis-
tance was observed despite extensive passaging of the virus in the
presence of Hsp90 inhibitors in cultured cells. Similarly, no drug resis-
tance was observed in viruses recovered from Hsp90 inhibitor treated
mice. The lack of viral drug resistance to Hsp90 inhibitors suggests
such an antiviral approach may be particularly useful for treatment
of chronic viral infections and treatment of RNA virus infections for
which drug resistance is most frequently observed.
The feasibility of transitioning Hsp90 inhibitors for antiviral use in
humans is further supported by the fact that Hsp90 constitutes a
highly druggable target. To date, numerous structurally diverse phar-
macological inhibitors have been identiﬁed. The majority of these in-
hibit Hsp90 by blocking ATP binding, although inhibitors that block
alternate sites on Hsp90 have also been identiﬁed. Moreover, Hsp90
activity is inhibited by acetylation [100] and histone deacetylase
(HDAC) inhibitors have been reported to block Hsp90 activity
[101–103]. The fact that Hsp90 inhibitors possess anti-cancer activity
and cancer cells display ~100 fold hypersensitivity to Hsp90 inhibi-
tion relative to normal cells has led to the synthesis and human eval-
uation of many Hsp90 inhibitors, the most advanced of which are
currently undergoing phase III clinical trials [104]. From data avail-
able to date, Hsp90 inhibitors appear to be reasonably well tolerated
at concentrations sufﬁcient for anticancer activity and show good tis-
sue distribution. Importantly, for an acute viral infection, the course of
inhibitor administration would be much shorter than those currently
used for cancer, thus potentially lessening side effects observed in the
much longer cancer therapies. Similarly, HDAC inhibitors are used in
the clinic for cancer treatment. Together, these results show that
Hsp90 inhibitors are safe for use in humans and could provide a via-
ble antiviral therapeutic strategy.
Additional important consideration regarding the use of Hsp90
inhibitors as antivirals comes from the role of Hsp90 in inﬂamma-
tion, immunology, cellular antiviral defense pathways, and apoptosis
[84,105]. Hsp90 inhibitors have been shown to reduce inﬂammation
[106–108]. This property may be useful during viral infections where
pathology is in part due to inﬂammatory processes. Additional roles of
Hsp90 in folding and activity of intracellular antiviral and inﬂammatory
responses, such as interferon regulatory factor 3 (IRF3), TBK1, and the
double-stranded RNA activated protein kinase (PKR) [109,110], may
play important roles in modulating the course of viral infection during
treatment with Hsp90 inhibitors.
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Proper folding is the essential ritual undergone by all proteins to
achieve their correct structure and activity. Although it is clear that
all viruses depend on the host chaperone machinery to fold their pro-
teins, most of the mechanisms and cellular factors underlying viral
protein homeostasis are still to be unveiled. Understanding this fasci-
nating process is likely to reveal many important principles and as-
pects of chaperone function that are fundamental to not only viral
biology but likely relevant to our understanding of normal protein
homeostasis. With regard to broad-spectrum therapeutic avenues to
combat viral infection, Hsp90 inhibitors hold considerable promise,
particularly as new compounds with low toxicity and high speciﬁcity
emerge. Characterization of speciﬁc co-chaperones involved in viral
replication may provide additional targets to develop antivirals with
fewer pleiotropic side effects. Nonetheless, the success of Hsp90 in-
hibitors for anticancer therapies, and the fact that many Hsp90 inhib-
itors are relatively well tolerated, bode well for harnessing them to be
used as antivirals. To further support the development of Hsp90 in-
hibitors as antiviral therapeutics, future efforts should be aimed at
careful evaluation of both the effectiveness and toxicity of Hsp90 in-
hibitors in animal models of infection for those viral infection where
good animal models exist (e.g. inﬂuenza virus, coxsackievirus, HSV).
Finally, it is important to note that Hsp90 does not work alone,
and other chaperones, such as Hsp70, are also conscripted to facilitate
viral protein folding and propagation. Hence, comprehensive under-
standing of chaperone use during viral infection will provide new in-
sight into viral replication mechanisms and potential therapeutics.
Acknowledgements
We thank Dr. Raul Andino for useful discussions and Dr. Christine
Livingston for comments on the manuscript. Work in the Frydman lab
is supported by NIH grant GM56433. S.T. acknowledges support of
grants-in-aid from the Naito Foundation and the Uehara Memorial
Foundation.
References
[1] J. Frydman, Folding of newly translated proteins in vivo: the role of molecular
chaperones, Annu. Rev. Biochem. 70 (2001) 603–647.
[2] J.C. Young, V.R. Agashe, K. Siegers, F.U. Hartl, Pathways of chaperone-mediated
protein folding in the cytosol, Nat. Rev. Mol. Cell Biol. 5 (2004) 781–791.
[3] M. Taipale, D.F. Jarosz, S. Lindquist, HSP90 at the hub of protein homeostasis:
emerging mechanistic insights, Nat. Rev. Mol. Cell Biol. 11 (2010) 515–528.
[4] B. Chen, W.H. Piel, L. Gui, E. Bruford, A. Monteiro, The HSP90 family of genes in
the human genome: insights into their divergence and evolution, Genomics 86
(2005) 627–637.
[5] E.G. Mimnaugh, C. Chavany, L. Neckers, Polyubiquitination and proteasomal
degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by
geldanamycin, J. Biol. Chem. 271 (1996) 22796–22801.
[6] C. Schneider, L. Sepp-Lorenzino, E. Nimmesgern, O. Ouerfelli, S. Danishefsky, N.
Rosen, F.U. Hartl, Pharmacologic shifting of a balance between protein refolding
and degradation mediated by Hsp90, Proc. Natl. Acad. Sci. U. S. A. 93 (1996)
14536–14541.
[7] L.H. Pearl, C. Prodromou, Structure and mechanism of the Hsp90 molecular
chaperone machinery, Annu. Rev. Biochem. 75 (2006) 271–294.
[8] K.A. Krukenberg, T.O. Street, L.A. Lavery, D.A. Agard, Conformational dynamics of
the molecular chaperone Hsp90, Q. Rev. Biophys. 44 (2011) 229–255.
[9] A. Chadli, I. Bouhouche, W. Sullivan, B. Stensgard, N. McMahon, M.G. Catelli, D.O.
Toft, Dimerization and N-terminal domain proximity underlie the function of
the molecular chaperone heat shock protein 90, Proc. Natl. Acad. Sci. U. S. A.
97 (2000) 12524–12529.
[10] C. Prodromou, B. Panaretou, S. Chohan, G. Siligardi, R. O'Brien, J.E. Ladbury, S.M.
Roe, P.W. Piper, L.H. Pearl, The ATPase cycle of Hsp90 drives a molecular ‘clamp’
via transient dimerization of the N-terminal domains, EMBO J. 19 (2000)
4383–4392.
[11] A.K. Mandal, P.A. Gibney, N.B. Nillegoda, M.A. Theodoraki, A.J. Caplan, K.A. Morano,
Hsp110 chaperones control client fate determination in the hsp70–Hsp90 chaper-
one system, Mol. Biol. Cell 21 (2010) 1439–1448.
[12] D.L. Riggs, M.B. Cox, J. Cheung-Flynn, V. Prapapanich, P.E. Carrigan, D.F. Smith,
Functional speciﬁcity of co-chaperone interactions with Hsp90 client proteins,
Crit. Rev. Biochem. Mol. Biol. 39 (2004) 279–295.[13] M.A. Theodoraki, A.J. Caplan, Quality control and fate determination of Hsp90 client
proteins, Biochim. Biophys. Acta (in press), doi:10.1016/j.bbamcr.2011.08.006.
[14] L.H. Pearl, Hsp90 and Cdc37— a chaperone cancer conspiracy, Curr. Opin. Genet.
Dev. 15 (2005) 55–61.
[15] S. Kimmins, T.H. MacRae, Maturation of steroid receptors: an example of func-
tional cooperation among molecular chaperones and their associated proteins,
Cell Stress Chaperones 5 (2000) 76–86.
[16] W.B. Pratt, D.O. Toft, Regulation of signaling protein function and trafﬁcking by
the hsp90/hsp70-based chaperone machinery, Exp. Biol. Med. (Maywood) 228
(2003) 111–133.
[17] C.A. Dickey, J. Koren, Y.J. Zhang, Y.F. Xu, U.K. Jinwal, M.J. Birnbaum, B. Monks, M.
Sun, J.Q. Cheng, C. Patterson, R.M. Bailey, J. Dunmore, S. Soresh, C. Leon, D. Morgan,
L. Petrucelli, Akt and CHIP coregulate tau degradation through coordinated interac-
tions, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 3622–3627.
[18] S. Murata, T. Chiba, K. Tanaka, CHIP: a quality-control E3 ligase collaborating
with molecular chaperones, Int. J. Biochem. Cell Biol. 35 (2003) 572–578.
[19] A.J. Caplan, A.K. Mandal, M.A. Theodoraki, Molecular chaperones and protein ki-
nase quality control, Trends Cell Biol. 17 (2007) 87–92.
[20] B.H. Kang, J. Plescia, T. Dohi, J. Rosa, S.J. Doxsey, D.C. Altieri, Regulation of tumor
cell mitochondrial homeostasis by an organelle-speciﬁc Hsp90 chaperone net-
work, Cell 131 (2007) 257–270.
[21] O. Stemmann, A. Neidig, T. Kocher, M. Wilm, J. Lechner, Hsp90 enables
Ctf13p/Skp1p to nucleate the budding yeast kinetochore, Proc. Natl. Acad. Sci.
U. S. A. 99 (2002) 8585–8590.
[22] A.J. McClellan, Y. Xia, A.M. Deutschbauer, R.W. Davis, M. Gerstein, J. Frydman, Di-
verse cellular functions of the Hsp90 molecular chaperone uncovered using sys-
tems approaches, Cell 131 (2007) 121–135.
[23] L.B. Peterson, B.S. Blagg, To fold or not to fold: modulation and consequences of
Hsp90 inhibition, Future Med. Chem. 1 (2009) 267–283.
[24] B.C. Freeman, K.R. Yamamoto, Disassembly of transcriptional regulatory com-
plexes by molecular chaperones, Science 296 (2002) 2232–2235.
[25] M.V. Blagosklonny, J. Toretsky, S. Bohen, L. Neckers, Mutant conformation of p53
translated in vitro or in vivo requires functional HSP90, Proc. Natl. Acad. Sci. U. S.
A. 93 (1996) 8379–8383.
[26] L. Whitesell, S.L. Lindquist, HSP90 and the chaperoning of cancer, Nat. Rev. Can-
cer 5 (2005) 761–772.
[27] P. Workman, Combinatorial attack on multistep oncogenesis by inhibiting the
Hsp90 molecular chaperone, Cancer Lett. 206 (2004) 149–157.
[28] K. Jhaveri, T. Taldone, S. Modi, G. Chiosis, Advances in the clinical development
of heat shock protein 90 (Hsp90) inhibitors in cancers, Biochim. Biophys. Acta
(in press), doi:10.1016/j.bbamcr.2011.10.008.
[29] M.J. Drysdale, P.A. Brough, A. Massey, M.R. Jensen, J. Schoepfer, Targeting Hsp90
for the treatment of cancer, Curr. Opin. Drug Discov. Devel. 9 (2006) 483–495.
[30] P.D. Nagy, R.Y. Wang, J. Pogany, A. Hafren, K. Makinen, Emerging picture of host
chaperone and cyclophilin roles in RNA virus replication, Virology 411 (2011)
374–382.
[31] D.C. Mah, G. Leone, J.M. Jankowski, P.W. Lee, The N-terminal quarter of reovirus
cell attachment protein sigma 1 possesses intrinsic virion-anchoring function,
Virology 179 (1990) 95–103.
[32] L. Nagata, S.A. Masri, R.T. Pon, P.W. Lee, Analysis of functional domains on reovi-
rus cell attachment protein sigma 1 using cloned S1 gene deletion mutants, Vi-
rology 160 (1987) 162–168.
[33] R. Geller, M. Vignuzzi, R. Andino, J. Frydman, Evolutionary constraints on
chaperone-mediated folding provide an antiviral approach refractory to devel-
opment of drug resistance, Genes Dev. 21 (2007) 195–205.
[34] J.J. Hung, C.S. Chung, W. Chang, Molecular chaperone Hsp90 is important for
vaccinia virus growth in cells, J. Virol. 76 (2002) 1379–1390.
[35] M.G. Rossmann, Constraints on the assembly of spherical virus particles, Virolo-
gy 134 (1984) 1–11.
[36] J.K. Pfeiffer, K. Kirkegaard, Increased ﬁdelity reduces poliovirus ﬁtness and viru-
lence under selective pressure in mice, PLoS Pathog. 1 (2005) e11.
[37] M. Vignuzzi, J.K. Stone, R. Andino, Ribavirin and lethal mutagenesis of poliovi-
rus: molecular mechanisms, resistance and biological implications, Virus Res.
107 (2005) 173–181.
[38] M. Vignuzzi, J.K. Stone, J.J. Arnold, C.E. Cameron, R. Andino, Quasispecies diversi-
ty determines pathogenesis through cooperative interactions in a viral popula-
tion, Nature 439 (2006) 344–348.
[39] S. Crowder, K. Kirkegaard, Trans-dominant inhibition of RNA viral replication
can slow growth of drug-resistant viruses, Nat. Genet. 37 (2005) 701–709.
[40] R.C. Hirsch, J.E. Lavine, L.J. Chang, H.E. Varmus, D. Ganem, Polymerase gene prod-
ucts of hepatitis B viruses are required for genomic RNA packaging as well as for
reverse transcription, Nature 344 (1990) 552–555.
[41] J. Hu, D. Anselmo, In vitro reconstitution of a functional duck hepatitis B virus re-
verse transcriptase: posttranslational activation by Hsp90, J. Virol. 74 (2000)
11447–11455.
[42] J. Hu, D. Toft, D. Anselmo, X. Wang, In vitro reconstitution of functional hepadna-
virus reverse transcriptase with cellular chaperone proteins, J. Virol. 76 (2002)
269–279.
[43] J. Hu, D.O. Toft, C. Seeger, Hepadnavirus assembly and reverse transcription re-
quire a multi-component chaperone complex which is incorporated into nucle-
ocapsids, EMBO J. 16 (1997) 59–68.
[44] X. Wang, N. Grammatikakis, J. Hu, Role of p50/CDC37 in hepadnavirus assembly
and replication, J. Biol. Chem. 277 (2002) 24361–24367.
[45] J. Hu, D. Flores, D. Toft, X. Wang, D. Nguyen, Requirement of heat shock protein
90 for human hepatitis B virus reverse transcriptase function, J. Virol. 78 (2004)
13122–13131.
705R. Geller et al. / Biochimica et Biophysica Acta 1823 (2012) 698–706[46] J. Hu, C. Seeger, Hsp90 is required for the activity of a hepatitis B virus reverse
transcriptase, Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 1060–1064.
[47] F. Momose, T. Naito, K. Yano, S. Sugimoto, Y. Morikawa, K. Nagata, Identiﬁcation
of Hsp90 as a stimulatory host factor involved in inﬂuenza virus RNA synthesis,
J. Biol. Chem. 277 (2002) 45306–45314.
[48] T. Naito, F. Momose, A. Kawaguchi, K. Nagata, Involvement of Hsp90 in assembly
and nuclear import of inﬂuenza virus RNA polymerase subunits, J. Virol. 81
(2007) 1339–1349.
[49] G. Chase, T. Deng, E. Fodor, B.W. Leung, D. Mayer, M. Schwemmle, G. Brownlee,
Hsp90 inhibitors reduce inﬂuenza virus replication in cell culture, Virology 377
(2008) 431–439.
[50] A.D. Burch, S.K. Weller, Nuclear sequestration of cellular chaperone and protea-
somal machinery during herpes simplex virus type 1 infection, J. Virol. 78
(2004) 7175–7185.
[51] A.D. Burch, S.K. Weller, Herpes simplex virus type 1 DNA polymerase requires
the mammalian chaperone hsp90 for proper localization to the nucleus, J.
Virol. 79 (2005) 10740–10749.
[52] Y.H. Li, P.Z. Tao, Y.Z. Liu, J.D. Jiang, Geldanamycin, a ligand of heat shock protein
90, inhibits the replication of herpes simplex virus type 1 in vitro, Antimicrob.
Agents Chemother. 48 (2004) 867–872.
[53] W. Basha, R. Kitagawa, M. Uhara, H. Imazu, K. Uechi, J. Tanaka, Geldanamycin,
a potent and speciﬁc inhibitor of Hsp90, inhibits gene expression and replica-
tion of human cytomegalovirus, Antivir. Chem. Chemother. 16 (2005)
135–146.
[54] C.A. Kyratsous, S.J. Silverstein, BAG3, a host cochaperone, facilitates varicella-
zoster virus replication, J. Virol. 81 (2007) 7491–7503.
[55] E.A. Nollen, A.E. Kabakov, J.F. Brunsting, B. Kanon, J. Hohfeld, H.H. Kampinga,
Modulation of in vivo HSP70 chaperone activity by Hip and Bag-1, J. Biol.
Chem. 276 (2001) 4677–4682.
[56] M. Kabbage, M.B. Dickman, The BAG proteins: a ubiquitous family of chaperone
regulators, Cell. Mol. Life Sci. 65 (2008) 1390–1402.
[57] C.A. Kyratsous, S.J. Silverstein, The co-chaperone BAG3 regulates Herpes Simplex
Virus replication, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 20912–20917.
[58] K.M. Kampmueller, D.J. Miller, The cellular chaperone heat shock protein 90 fa-
cilitates Flock House virus RNA replication in Drosophila cells, J. Virol. 79 (2005)
6827–6837.
[59] K.M. Castorena, S.A. Weeks, K.A. Stapleford, A.M. Cadwallader, D.J. Miller, A
functional heat shock protein 90 chaperone is essential for efﬁcient ﬂock
house virus RNA polymerase synthesis in Drosophila cells, J. Virol. 81
(2007) 8412–8420.
[60] J.H. Connor, M.O. McKenzie, G.D. Parks, D.S. Lyles, Antiviral activity and RNA po-
lymerase degradation following Hsp90 inhibition in a range of negative strand
viruses, Virology 362 (2007) 109–119.
[61] G. Crevel, H. Bates, H. Huikeshoven, S. Cotterill, The Drosophila Dpit47 protein is
a nuclear Hsp90 co-chaperone that interacts with DNA polymerase alpha, J. Cell
Sci. 114 (2001) 2015–2025.
[62] S.E. Holt, D.L. Aisner, J. Baur, V.M. Tesmer, M. Dy, M. Ouellette, J.B. Trager,
G.B. Morin, D.O. Toft, J.W. Shay, W.E. Wright, M.A. White, Functional require-
ment of p23 and Hsp90 in telomerase complexes, Genes Dev. 13 (1999)
817–826.
[63] Y. Miyata, I. Yahara, p53-independent association between SV40 large T antigen
and the major cytosolic heat shock protein, HSP90, Oncogene 19 (2000)
1477–1484.
[64] E.T. Sawai, J.S. Butel, Association of a cellular heat shock protein with simian
virus 40 large T antigen in transformed cells, J. Virol. 63 (1989) 3961–3973.
[65] J.V. Gannon, D.P. Lane, p53 and DNA polymerase alpha compete for binding to
SV40 T antigen, Nature 329 (1987) 456–458.
[66] D. Dutta, S. Chattopadhyay, P. Bagchi, U.C. Halder, S. Nandi, A. Mukherjee, N.
Kobayashi, K. Taniguchi, M. Chawla-Sarkar, Active participation of cellular chap-
erone Hsp90 in regulating the function of rotavirus nonstructural protein 3
(NSP3), J. Biol. Chem. 286 (2011) 20065–20077.
[67] M. Harb, M.M. Becker, D. Vitour, C.H. Baron, P. Vende, S.C. Brown, S. Bolte, S.T.
Arold, D. Poncet, Nuclear localization of cytoplasmic poly(A)-binding protein
upon rotavirus infection involves the interaction of NSP3 with eIF4G and
RoXaN, J. Virol. 82 (2008) 11283–11293.
[68] Y.M. Michel, D. Poncet, M. Piron, K.M. Kean, A.M. Borman, Cap-poly(A) synergy
in mammalian cell-free extracts. Investigation of the requirements for poly(A)-
mediated stimulation of translation initiation, J. Biol. Chem. 275 (2000)
32268–32276.
[69] P. Vende, M. Piron, N. Castagne, D. Poncet, Efﬁcient translation of rotavirus
mRNA requires simultaneous interaction of NSP3 with the eukaryotic trans-
lation initiation factor eIF4G and the mRNA 3′ end, J. Virol. 74 (2000)
7064–7071.
[70] D. Dutta, P. Bagchi, A. Chatterjee, M.K. Nayak, A. Mukherjee, S. Chattopadhyay, S.
Nagashima, N. Kobayashi, S. Komoto, K. Taniguchi, M. Chawla-Sarkar, The mo-
lecular chaperone heat shock protein-90 positively regulates rotavirus infection,
Virology 391 (2009) 325–333.
[71] S. Ujino, S. Yamaguchi, K. Shimotohno, H. Takaku, Heat-shock protein 90 is es-
sential for stabilization of the hepatitis C virus nonstructural protein NS3, J.
Biol. Chem. 284 (2009) 6841–6846.
[72] L. Waxman, M. Whitney, B.A. Pollok, L.C. Kuo, P.L. Darke, Host cell factor require-
ment for hepatitis C virus enzyme maturation, Proc. Natl. Acad. Sci. U. S. A. 98
(2001) 13931–13935.
[73] T. Okamoto, Y. Nishimura, T. Ichimura, K. Suzuki, T. Miyamura, T. Suzuki, K.
Moriishi, Y. Matsuura, Hepatitis C virus RNA replication is regulated by FKBP8
and Hsp90, EMBO J. 25 (2006) 5015–5025.[74] S. Taguwa, H. Kambara, H. Omori, H. Tani, T. Abe, Y. Mori, T. Suzuki, T. Yoshimori,
K. Moriishi, Y. Matsuura, Cochaperone activity of human butyrate-induced tran-
script 1 facilitates hepatitis C virus replication through an Hsp90-dependent
pathway, J. Virol. 83 (2009) 10427–10436.
[75] L. Aragones, S. Guix, E. Ribes, A. Bosch, R.M. Pinto, Fine-tuning translation kinet-
ics selection as the driving force of codon usage bias in the hepatitis A virus cap-
sid, PLoS Pathog. 6 (2010) e1000797.
[76] G. Leone, M.C. Coffey, R. Gilmore, R. Duncan, L. Maybaum, P.W. Lee, C-terminal
trimerization, but not N-terminal trimerization, of the reovirus cell attachment
protein Is a posttranslational and Hsp70/ATP-dependent process, J. Biol. Chem.
271 (1996) 8466–8471.
[77] G. Leone, L. Maybaum, P.W. Lee, The reovirus cell attachment protein possesses
two independently active trimerization domains: basis of dominant negative ef-
fects, Cell 71 (1992) 479–488.
[78] R. Gilmore, M.C. Coffey, P.W. Lee, Active participation of Hsp90 in the biogenesis
of the trimeric reovirus cell attachment protein sigma1, J. Biol. Chem. 273
(1998) 15227–15233.
[79] Y.G. Zhao, R. Gilmore, G. Leone, M.C. Coffey, B. Weber, P.W. Lee, Hsp90 phos-
phorylation is linked to its chaperoning function. Assembly of the reovirus cell
attachment protein, J. Biol. Chem. 276 (2001) 32822–32827.
[80] J. Sekiguchi, S. Shuman, Novobiocin inhibits vaccinia virus replication by block-
ing virus assembly, Virology 235 (1997) 129–137.
[81] J. Sekiguchi, J.T. Stivers, A.S. Mildvan, S. Shuman, Mechanism of inhibition of vac-
cinia DNA topoisomerase by novobiocin and coumermycin, J. Biol. Chem. 271
(1996) 2313–2322.
[82] Z.Z. Zheng, J. Miao, M. Zhao, M. Tang, A.E. Yeo, H. Yu, J. Zhang, N.S. Xia, Role of
heat-shock protein 90 in hepatitis E virus capsid trafﬁcking, J. Gen. Virol. 91
(2010) 1728–1736.
[83] S. Tsutsumi, L. Neckers, Extracellular heat shock protein 90: a role for a molecu-
lar chaperone in cell motility and cancer metastasis, Cancer Sci. 98 (2007)
1536–1539.
[84] M.F. Tsan, B. Gao, Heat shock proteins and immune system, J. Leukoc. Biol. 85
(2009) 905–910.
[85] A. Cabrera-Hernandez, C. Thepparit, L. Suksanpaisan, D.R. Smith, Dengue virus
entry into liver (HepG2) cells is independent of hsp90 and hsp70, J. Med.
Virol. 79 (2007) 386–392.
[86] J. Reyes-Del Valle, S. Chavez-Salinas, F. Medina, R.M. Del Angel, Heat shock pro-
tein 90 and heat shock protein 70 are components of dengue virus receptor
complex in human cells, J. Virol. 79 (2005) 4557–4567.
[87] S. Chavez-Salinas, I. Ceballos-Olvera, J. Reyes-Del Valle, F. Medina, R.M. Del
Angel, Heat shock effect upon dengue virus replication into U937 cells, Virus
Res. 138 (2008) 111–118.
[88] T.W. Lin, C.W. Lo, S.Y. Lai, R.J. Fan, C.J. Lo, Y.M. Chou, R. Thiruvengadam, A.H.
Wang, M.Y. Wang, Chicken heat shock protein 90 is a component of the putative
cellular receptor complex of infectious bursal disease virus, J. Virol. 81 (2007)
8730–8741.
[89] B. O'Keeffe, Y. Fong, D. Chen, S. Zhou, Q. Zhou, Requirement for a kinase-speciﬁc
chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer respon-
sible for P-TEFb-mediated tat stimulation of HIV-1 transcription, J. Biol. Chem.
275 (2000) 279–287.
[90] L. Vozzolo, B. Loh, P.J. Gane, M. Tribak, L. Zhou, I. Anderson, E. Nyakatura, R.G.
Jenner, D. Selwood, A. Fassati, Gyrase B inhibitor impairs HIV-1 replication by
targeting Hsp90 and the capsid protein, J. Biol. Chem. 285 (2010) 39314–39328.
[91] M. Thome, P. Schneider, K. Hofmann, H. Fickenscher, E. Meinl, F. Neipel, C. Matt-
mann, K. Burns, J.L. Bodmer, M. Schroter, C. Scafﬁdi, P.H. Krammer, M.E. Peter, J.
Tschopp, Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by
death receptors, Nature 386 (1997) 517–521.
[92] C.C. Tomlinson, B. Damania, The K1 protein of Kaposi's sarcoma-associated her-
pesvirus activates the Akt signaling pathway, J. Virol. 78 (2004) 1918–1927.
[93] N. Field, W. Low, M. Daniels, S. Howell, L. Daviet, C. Boshoff, M. Collins, KSHV
vFLIP binds to IKK-gamma to activate IKK, J. Cell Sci. 116 (2003) 3721–3728.
[94] K.W. Wen, B. Damania, Hsp90 and Hsp40/Erdj3 are required for the expression
and anti-apoptotic function of KSHV K1, Oncogene 29 (2010) 3532–3544.
[95] H. Kawakami, M. Tomita, T. Okudaira, C. Ishikawa, T. Matsuda, Y. Tanaka, T.
Nakazato, N. Taira, K. Ohshiro, N. Mori, Inhibition of heat shock protein-90 mod-
ulates multiple functions required for survival of human T-cell leukemia virus
type I-infected T-cell lines and adult T-cell leukemia cells, Int. J. Cancer 120
(2007) 1811–1820.
[96] Y.K. Jeon, C.H. Park, K.Y. Kim, Y.C. Li, J. Kim, Y.A. Kim, J.H. Paik, B.K. Park, C.W.
Kim, Y.N. Kim, The heat-shock protein 90 inhibitor, geldanamycin, induces apo-
ptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt
down-regulation, J. Pathol. 213 (2007) 170–179.
[97] E. De Clercq, Antivirals and antiviral strategies, Nat. Rev. Microbiol. 2 (2004)
704–720.
[98] P.A. zur Wiesch, R. Kouyos, J. Engelstadter, R.R. Regoes, S. Bonhoeffer, Population
biological principles of drug-resistance evolution in infectious diseases, Lancet
Infect. Dis. 11 (2011) 236–247.
[99] S. Nakagawa, T. Umehara, C. Matsuda, S. Kuge, M. Sudoh, M. Kohara, Hsp90 in-
hibitors suppress HCV replication in replicon cells and humanized liver mice,
Biochem. Biophys. Res. Commun. 353 (2007) 882–888.
[100] M.A. Glozak, N. Sengupta, X. Zhang, E. Seto, Acetylation and deacetylation of
non-histone proteins, Gene 363 (2005) 15–23.
[101] L. Fuino, P. Bali, S. Wittmann, S. Donapaty, F. Guo, H. Yamaguchi, H.G. Wang, P.
Atadja, K. Bhalla, Histone deacetylase inhibitor LAQ824 down-regulates Her-2
and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine,
and epothilone B, Mol. Cancer Ther. 2 (2003) 971–984.
706 R. Geller et al. / Biochimica et Biophysica Acta 1823 (2012) 698–706[102] R. Nimmanapalli, L. Fuino, P. Bali, M. Gasparetto, M. Glozak, J. Tao, L. Moscinski,
C. Smith, J. Wu, R. Jove, P. Atadja, K. Bhalla, Histone deacetylase inhibitor
LAQ824 both lowers expression and promotes proteasomal degradation of
Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory
chronic myelogenous leukemia-blast crisis cells, Cancer Res. 63 (2003)
5126–5135.
[103] X. Yu, Z.S. Guo, M.G. Marcu, L. Neckers, D.M. Nguyen, G.A. Chen, D.S. Schrump,
Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by
depsipeptide FR901228, J. Natl. Cancer Inst. 94 (2002) 504–513.
[104] Y.S. Kim, S.V. Alarcon, S. Lee, M.J. Lee, G. Giaccone, L. Neckers, J.B. Trepel, Update
on Hsp90 inhibitors in clinical trial, Curr. Top. Med. Chem. 9 (2009) 1479–1492.
[105] A.L. Joly, G. Wettstein, G. Mignot, F. Ghiringhelli, C. Garrido, Dual role of heat
shock proteins as regulators of apoptosis and innate immunity, J. Innate
Immun. 2 (2010) 238–247.
[106] C. Dello Russo, P.E. Polak, P.R. Mercado, A. Spagnolo, A. Sharp, P. Murphy, A.
Kamal, F.J. Burrows, L.C. Fritz, D.L. Feinstein, The heat-shock protein 90 inhibitor
17-allylamino-17-demethoxygeldanamycin suppresses glial inﬂammatory re-
sponses and ameliorates experimental autoimmune encephalomyelitis, J. Neu-
rochem. 99 (2006) 1351–1362.
[107] J.M. Kim, D.H. Lee, J.S. Kim, J.Y. Lee, H.G. Park, Y.J. Kim, Y.K. Oh, H.C. Jung, S.I. Kim,
5,7-dihydroxy-3,4,6-trimethoxyﬂavone inhibits the inﬂammatory effects in-
duced by Bacteroides fragilis enterotoxin via dissociating the complex of heat
shock protein 90 and I kappaB alpha and I kappaB kinase-gamma in intestinal
epithelial cell culture, Clin. Exp. Immunol. 155 (2009) 541–551.
[108] J.W. Rice, J.M. Veal, R.P. Fadden, A.F. Barabasz, J.M. Partridge, T.E. Barta, L.G.
Dubois, K.H. Huang, S.R. Mabbett, M.A. Silinski, P.M. Steed, S.E. Hall, Small
molecule inhibitors of Hsp90 potently affect inﬂammatory disease pathways
and exhibit activity in models of rheumatoid arthritis, Arthritis Rheum. 58
(2008) 3765–3775.
[109] O. Donze, T. Abbas-Terki, D. Picard, The Hsp90 chaperone complex is both a fa-
cilitator and a repressor of the dsRNA-dependent kinase PKR, EMBO J. 20 (2001)
3771–3780.
[110] K. Yang, H. Shi, R. Qi, S. Sun, Y. Tang, B. Zhang, C. Wang, Hsp90 regulates activa-
tion of interferon regulatory factor 3 and TBK-1 stabilization in Sendai virus-
infected cells, Mol. Biol. Cell 17 (2006) 1461–1471.[111] M. Kotsiopriftis, J.E. Tanner, C. Alﬁeri, Heat shock protein 90 expression in
Epstein-Barr virus-infected B cells promotes gammadelta T-cell proliferation in
vitro, J. Virol. 79 (2005) 7255–7261.
[112] X. Sun, E.A. Barlow, S. Ma, S.R. Hagemeier, S.J. Duellman, R.R. Burgess, J. Tellam,
R. Khanna, S.C. Kenney, Hsp90 inhibitors block outgrowth of EBV-infected ma-
lignant cells in vitro and in vivo through an EBNA1-dependent mechanism,
Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 3146–3151.
[113] S. Jindal, R.A. Young, Vaccinia virus infection induces a stress response that leads
to association of Hsp70 with viral proteins, J. Virol. 66 (1992) 5357–5362.
[114] T. Okamoto, H. Omori, Y. Kaname, T. Abe, Y. Nishimura, T. Suzuki, T. Miyamura, T.
Yoshimori, K. Moriishi, Y. Matsuura, A single-amino-acid mutation in hepatitis C
virus NS5A disrupting FKBP8 interaction impairs viral replication, J. Virol. 82
(2008) 3480–3489.
[115] S. Taguwa, T. Okamoto, T. Abe, Y. Mori, T. Suzuki, K. Moriishi, Y. Matsuura,
Human butyrate-induced transcript 1 interacts with hepatitis C virus NS5A
and regulates viral replication, J. Virol. 82 (2008) 2631–2641.
[116] S. Basta, R. Stoessel, M. Basler, M. van den Broek, M. Groettrup, Cross-presenta-
tion of the long-lived lymphocytic choriomeningitis virus nucleoprotein does
not require neosynthesis and is enhanced via heat shock proteins, J. Immunol.
175 (2005) 796–805.
[117] S.A. Weeks, D.J. Miller, The heat shock protein 70 cochaperone YDJ1 is required
for efﬁcient membrane-speciﬁc ﬂock house virus RNA replication complex as-
sembly and function in Saccharomyces cerevisiae, J. Virol. 82 (2008) 2004–2012.
[118] C. Liu, C. Erlichman, C.J. McDonald, J.N. Ingle, P. Zollman, I. Iankov, S.J. Russell, E.
Galanis, Heat shock protein inhibitors increase the efﬁcacy of measles virother-
apy, Gene Ther. 15 (2008) 1024–1034.
[119] D.R. Smith, S. McCarthy, A. Chrovian, G. Olinger, A. Stossel, T.W. Geisbert, L.E.
Hensley, J.H. Connor, Inhibition of heat-shock protein 90 reduces Ebola virus
replication, Antiviral Res. 87 (2010) 187–194.
[120] A. Vendeville, F. Rayne, A. Bonhoure, N. Bettache, P. Montcourrier, B. Beaumelle,
HIV-1 Tat enters T cells using coated pits before translocating from acidiﬁed endo-
somes and eliciting biological responses, Mol. Biol. Cell 15 (2004) 2347–2360.
[121] J. Beck, M. Nassal, Efﬁcient Hsp90-independent in vitro activation by Hsc70 and
Hsp40 of duck hepatitis B virus reverse transcriptase, an assumed Hsp90 client
protein, J. Biol. Chem. 278 (2003) 36128–36138.
